Table 1 Trial of registered MSCs in the treatment of COVID-19
From: Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19
Registration no | Title | Cell source | No. patients | Methods |
|---|---|---|---|---|
ChiCTR2000029580 | A prospective, single-blind, randomized controlled trial for Ruxolitinib combined with mesenchymal stem cell infusion in the treatment of patients with severe 2019-nCoV pneumonia | Ruxolitinib in combination with MSCs | 35 | NA |
ChiCTR2000029990 | Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19) | MSCs | 60 | NA |
ChiCTR2000030020 | The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19) | MSCs | 20 | NA |
ChiCTR2000030088 | Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) | Umbilical cord Wharton’s Jelly derived MSC | 20 | IV injection of Wharton's Jelly mesenchymal stem cells (1 × 106/kg), cell suspension volume: 40 ml |
ChiCTR2000030116 | Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19) | hUC-MSCs | 16 | Different stem cell doses (specific unknown) |
ChiCTR2000030138 | Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19) | hUC-MSCs | 30 | NA |
ChiCTR2000030173 | Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration | hUC-MSCs | 30 | NA |
ChiCTR2000030261 | A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19) | MSCs exosomes | 13 | Aerosol inhalation of exosomes(Specific unknown) |
ChiCTR2000030484 | HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19) | HU-MSCs and Exosomes | 30 | NA |
ChiCTR2000030835 | Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19) | hUC-MSCs | 20 | NA |
ChiCTR2000030866 | Open-label, observational study of human umbilical cord-derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19) | hUC-MSCs | 20 | Intravenous infusion of 1 × 106 cells/kg/time on day 0, 3, 6 |
ChiCTR2000030944 | Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID-19) | Human NK cells and MSCs transplantation | 10 | NA |
ChiCTR2000031319 | Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe novel coronavirus pneumonia (COVID-19) patients | Allogeneic Human Dental Pulp MSC | 10 | NA |
ChiCTR2000031430 | Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19)-induced pulmonary fibrosis | hUC-MSCs | 100 | 4 × 107/ times, intravenous injection on days 0, 3, and 6 for a total of 3 times |
ChiCTR2000031494 | Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) | MSCs | 18 | NA |
NCT04252118 | Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19 | MSCs | 20 | 3 times of MSCs(3.0 × 107 MSCs intravenously at Day 0, Day 3, Day 6) |
NCT04392778 | What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study) | MSCs | 30 | 3.0 × 106 cells/kg (3 times, on Day 0, Day 3, Day 6) |
NCT04269525 | Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection | UC-MSCs | 16 | 3.3 × 107 cell number / 50 ml / bag, 3 bags each time. on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day |
NCT04273646 | Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19 | UC-MSCs | 48 | 4 times, 0.5 × 106 cells/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7 |
NCT04288102 | A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients | UC-MSCs | 100 | 4.0 × 107cells/times (3 times, Day 0, Day 3, Day 6.) |
NCT04346368 | Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients With Coronavirus Disease 2019 (COVID-19): A Phase 1/2 Randomized Controlled Trial | BM-MSCs | 20 | 1 × 106 /kg body weight intravenously at Day 1 |
NCT04397796 | Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Of The Safety Of Therapeutic Treatment With Immunomodulatory Mesenchymal Stem Cells In Adults With COVID-19 Infection Requiring Mechanical Ventilation | BM-Allo.MSC | 45 | NA |
NCT04293692 | Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus | UC-MSCs | 24 | 0.5 × 106 cells/kg body weight suspended in 100 mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7 |
NCT04437823 | Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients | UC-MSCs | 20 | 5 × 105 cells/kg (3 times, Day 1, Day 3 and Day 5 |
NCT04456361 | A Study of Mesenchymal Stem Cells as a Treatment in Patients With Acute Respiratory Distress Syndrome Caused by COVID-19 | UC-MSCs | 9 | 1 × 108 cells/time (one time) |
NCT04313322 | Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells | WJ-MSCs | 5 | 1 × 106 cells/kg (3 times |
NCT04390152 | Safety and Efficacy of Intravenous Infusion of Wharton's Jelly Derived Mesenchymal Stem Cell Plus Standard Therapy for the Treatment of Patients With Acute Respiratory Distress Syndrome Diagnosis Due to COVID 19: A Randomized Controlled Trial | WJ-MSCs | 40 | 50 × 106 cells/time (2 times) |
NCT04315987 | Exploratory Clinical Study to Assess the Efficacy of NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia | NestaCell® MSCs | 90 | A dose of 2 × 107 cells will be administered IV on days 1, 3, 5 and 7 |
NCT04302519 | Clinical Study of Novel Coronavirus-Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells | Dental MSCs | 24 | 1 × 106 cells/kg (3 times, on Day1, Day 3 and Day 7) |
NCT04276987 | A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia | MSCs-derived exosomes | 24 | 5 times aerosol inhalation (2.0 × 108 nanovesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5) |
NCT04341610 | Allogeneic Adipose Tissue-Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study | A-MSCs | NA | 100 million cells diluted in 100Â ml saline |
NCT04331613 | Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS) | CAStem | 9 | 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg |
NCT04339660 | Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia | UC-MSCs | 30 | 1 × 106 cells /kg body weight suspended in 100 mL saline |
NCT04336254 | Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19: a Single-center, Prospective, Randomized Clinical Trial | Allogeneic Human Dental Pulp MSCs | 20 | Intravenous injection of 3.0 × 107 human dental pulp stem cells solution (30 ml) on day 1, day 4 and day 7, |
NCT04366323 | Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 | Adipose tissue-derived mesenchymal stem cells | 26 | 8 × 107 cells/time (two times) |
NCT04349631 | Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease | HB-adMSCs | 56 | Five times (dose not applicable) |
NCT04366063 | Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2–3 Clinical Trial | MSCs | 60 | 1 × 108 cells with or without extracellular vesicles (EVs) in two times (on Day 0, Day 2 for MSC and on Day 4, Day 6 for EVs) |
NCT04352803 | IV Infusion of Autologous Adipose-Derived Mesenchymal Cells for Abatement of Respiratory Compromise in SARS-CoV-2 Pandemic (COVID-19) | Autologous adipose MSC's (AMSCs) | 20 | 500,000/kg IV |
NCT04362189 | A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 | HB-adMSC | 100 | 100 million cells/dose(4 times, day 0, 3, 7, and 10) |
NCT04348461 | Two-treatment, Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19 | Allogeneic and expanded adipose-derived MSCs (AMSCs) | 100 | 1.5 × 106 cells/kg (two times) |
NCT03042143 | Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomized, Double-blind, Placebo-controlled Phase 2 Trial (COVID-19) | Human umbilical cord-derived CD362-enriched MSCs | 120 | Maximum tolerated dose from the phase 1 trial will be infused over 30 to 90Â min |
NCT04361942 | Double-Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV) | MSCs | 24 | Intravenous injection of 1 million MSV cells/Kg diluted in 100Â ml saline |
NCT04333368 | Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS | UCMSCs | 47 | 1 × 106 cells/kg (three times, Day 1, Day 3 and Day 5) |
NCT04416139 | Mesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot Study | MSCs | 10 | 1 million cells/Kg in a single dose |
NCT04428801 | Clinical Study for the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus 2019 (COVID-19) | autologous adipose-derived stem cells | 200 | Three doses of 200 million cells via intravenously infusion every three days |
NCT04348435 | A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19 | Allogeneic HB-adMSCs | 55 | 200 × 106 cells/time (5 times, Day 0, Day 2, Day 6, Day 10 and Day 14) |
NCT04444271 | Prospective, Randomized Phase 2 Clinical Trial of Mesenchymal Stem Cells(MSCs) for the Treatment of Coronavirus Disease 2019(COVID-19) | MSCs | 20 | 2 × 106 cells/kg (two times, Day 1 and Day7 |
NCT04429763 | Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 | UCBMSCs | 30 | One dose of 1 × 106 cells/Kg |
NCT04490486 | Phase I, Randomized, Double-Blinded, Placebo Control Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 With Moderate to Severe Symptoms | UCMSCs | 21 | 100 × 106 cells/time (two times, Day 1 and Day 3) |
NCT04457609 | Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients | UCMSCs | 40 | 1 × 106 cells/kgBW in 100 cc of 0.9% NaCl for 1 h |
NCT04486001 | COVID-19 Stem Cell Therapy: A Phase I Study of Intravenous Administration of Allogeneic Adipose Stem Cells | PSC-04 | 20 | NA |